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Tumor cellsThe effects of α-tocopheryl succinate (α-TOS), α-tocopheryl acetyl ether (α-TEA) and triphenylphosphonium-
tagged vitamin E succinate (mitochondrially targeted vitamin E succinate; MitoVES) on energy-related mito-
chondrial functions were determined in mitochondria isolated from AS-30D hepatoma and rat liver, bovine
heart sub-mitochondrial particles (SMPs), and in rodent and human carcinoma cell lines and rat hepatocytes.
In isolated mitochondria, MitoVES stimulated basal respiration and ATP hydrolysis, but inhibited net state 3
(ADP-stimulated) respiration and Ca2+ uptake, by collapsing the membrane potential at low doses (1–10 μM).
Uncoupledmitochondrial respiration and basal respiration of SMPswere inhibited by the three drugs at concen-
trations at least one order of magnitude higher and with different efﬁcacy: MitoVES>α-TEA>α-TOS. At high
doses (>10 μM), the respiratory complex II (CII) was the most sensitive MitoVES target. Acting as an uncoupler
at low doses, this agent stimulated total O2 uptake, collapsed Δψm, inhibited oxidative phosphorylation and in-
duced ATP depletion in rodent and human cancer cellsmore potently than in normal rat hepatocytes. These ﬁnd-
ings revealed that in situ tumor mitochondria are preferred targets of the drug, indicating its clinical relevance.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria and themitochondrial function have recently emerged
as attractive alternative targets for cancer therapy. It is now clear that a
variety of canonical anti-cancer drugs directly affect the mitochondrial
function, in addition to targeting DNA, microtubules or other cellular
sites. It is also possibly that speciﬁc perturbation of the mitochondrial
function has important clinical relevance [1,2]. Increasingly, mitochon-
dria are recognized to play an essential role in tumorigenesis through
diversemechanisms, e.g., mutagenesis by transfer and insertion of mito-
chondrial DNA (mtDNA) into nuclear DNA, altered expression and mu-
tation of mtDNA-encoded proteins, and mitochondrial ROS-dependenttriphenylphosphonium tagged
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rights reserved.stabilization of HIF-1α a key transcriptional factor that regulates tumor-
igenesis [3,4]. Mitochondria also seem involved in the maintenance of
the malignant phenotype through mechanisms possibly related to ATP
production [5,6].
Certain anti-cancer drugs such as cisplatin [7,8] preferentially bind
to mtDNA rather than to nuclear DNA. The histone-lacking nature of
mtDNA structure facilitates the access of drugs, while limited DNA
repair mechanisms in mitochondria enhance its mutation rates and
permanent damage induced by various agents, often implicating oxi-
dative stress [6,9]. The development of resistance to cisplatin in many
tumor cell lines also appears to be related to mitochondrial alterations
[10]. Several clinically used anti-cancer drugs such as adriamycin,
apoptolidin, or cisplatin also affect the mitochondrial function by
inhibiting the Krebs cycle (in particular 2-oxoglutarate dehydroge-
nase), the respiratory chain (complexes I to IV, CI–CIV) and/or the phos-
phorylation system (ATP synthase). In addition, these agents can impair
themitochondrial energy metabolism by inducing an uncoupling effect
and inhibition of oxidative phosphorylation following the collapse of
the H+ electrochemical gradient across the inner membrane (Δψm).
As a consequence, stimulation of electron transport and O2 consump-
tion by the respiratory chain ensue, and these events have been
shown to occur in both mitochondria and whole cells from non-tumor
and tumor tissues [reviewed in 1].
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succinate (α-TOS) andα-tocopheryl acetyl ether (α-TEA), and the pos-
itively charged triphenylphosphonium (TPP+)-tagged mitochondrially
targeted VE succinate (MitoVES) have emerged as a family of drugs
acting on mitochondria with potent anti-cancer activity against several
experimental and human carcinoma cells but only marginal, if any, ef-
fects on normal cells [11–13]. The molecular basis of apoptosis induced
by these agents stems from their interaction with the ubiquinone-
binding site of CII to stimulate ROS production [12–14]. VE analogues
also act as BH3 mimetic-like compounds, blocking the interaction
of the anti-apoptotic Bcl-2 family proteins with their pro-apoptotic
counterparts, resulting in cytochrome c release and caspase activation
[15; reviewed in 4,16].
To further deﬁne their mechanisms of action and to elucidate the
biochemical basis of their selective toxicity for cancer cells, a thor-
ough evaluation of the effects of the three anti-cancer VE analogues
on respiratory rates, generation of electrical membrane potential,
Ca2+ uptake, as well as ATP synthesis and hydrolysis in mitochondria,
sub-mitochondrial particles (SMPs) and cells was undertaken in the
present study.
2. Material and methods
2.1. SMPs, mitochondria and cells
Tightly coupled bovine heart SMPs were prepared by sonicating
mitochondrial suspensions in the presence of 20 mM succinate [17].
Tightly coupled rat liver and AS-30D hepatoma mitochondria
[18,19], the rodent AS-30D hepatoma, the human HeLa (cervix) carci-
noma cells [20,21], and rat hepatocytes [22] were obtained as previ-
ously described.
2.2. Experimental procedures for determination of energy-dependent
mitochondrial functions
Respiration of mitochondria was determined using a Clark-type O2
electrode in an air-saturated medium containing 120 mM KCl, 20 mM
MOPS, 0.5 mM EGTA, 5 mM K-phosphate, pH 7.2 (KMEPi buffer) and
the indicated oxidizable substrate at 37 °C. Respiration of SMPs was
measured in 250 mM sucrose, 10 mM HEPES, 1 mM EGTA, pH 7.3
(SHE buffer) and the indicated oxidizable substrate at 37 °C. Tumor
cells and hepatocytes were incubated in the Krebs–Ringer medium
(120 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM KH2PO4, 1.4 mM
CaCl2, 25 mM HEPES, pH 7.4) at 37 °C for evaluation of cellular respi-
ration supported by endogenous substrates. Respiration of intact cells
does not change by adding exogenous mitochondrial substrates such
as glutamine, glutamate, malate or succinate in short-term experi-
ments [20].
The O2 solubility at 2240 m altitude was 400 and 390 ng oxygen
atoms per ml at 37 °C in the KMEPi and SHE buffers, respectively,
and 380 ng oxygen atoms per ml at 37 °C in the Krebs–Ringer buffer.
The difference in the electrical potential across the inner mito-
chondrial membrane (Δψm) was estimated qualitatively in isolated
mitochondria by following the change in absorbance of 5 μM safranin
O at 554 minus 520 nm in a dual-wavelength spectrophotometer [23]
using mitochondria (0.5 mg protein/ml) incubated in the KMEPi buff-
er at 37 °C. Determination of the pH gradient in SMPs was carried out
as described elsewhere [24].
The Δψm in intact cells was determined by following the ﬂuores-
cence changes of rhodamine 6G [25,26]. Cells at 0.5 mg protein/ml
were incubated in Krebs–Ringer buffer at 37 °C under smooth stirring
with 0.25 μM rhodamine 6G (Sigma-Aldrich, St. Luis, MO, USA). The
excitation and emission wavelengths were 480 and 552 nm,
respectively.
The rate of ATP hydrolysis in intact mitochondria was determined
by following the rate of acidiﬁcation (scalar H+ release) with theﬂuorescence pH-sensitive probe pyranine [27]. The reaction medium
contained 120 mM KCl, 5 mM MgCl2, 0.1 mM EGTA, 1 mM HEPES pH
8.0, and 2 μM pyranine. Well-coupled isolated mitochondria (0.75 mg
protein/ml) were incubated for 2–5 min in the reaction medium at
37 °C. ATP at 1 mM and oligomycin at 5 μM were added to initiate
and stop the reaction, respectively. The excitation and emission wave-
lengths used were 450 and 507 nm, respectively. The ﬂuorescence sig-
nal was calibrated by the addition of a known amount of alkali at the
end of the experiment. It was assumed that the stoichiometry of scalar
H+/ATP hydrolyzed is 1 at pH 8 [28] and the rate of ATP hydrolysis was
corrected by subtracting the remaining rate of H+ release in the pres-
ence of oligomycin.
The Ca2+ uptake was assessed essentially as described previously
[29]. Mitochondria (0.78 mg protein/ml) were incubated in 120 mM
KCl, 20 mM MOPS pH 7.2, 2 mM Pi at 30 °C with 5 mM succinate,
1 μM rotenone, 100 μM CaCl2, 0.21 mM ADP, 1 μg oligomycin/ml,
and 50 μM arsenazo III. The changes in the absorbance difference at
685 minus 675 nm were followed in a Shimadzu UV-2501PC dual-
wavelength spectrophotometer under continuous gassing with 100%
O2 and gentle stirring.
2.3. Complex I and complex II activities
The CI and CII dehydrogenase activities were determined using
SMPs (13–52 μg protein/ml) incubated at 37 °C in the SHE medium
with 75–100 μM 2,6-dichlorophenol indophenol. The reaction was
started by adding succinate (0.25–2 mM) or NADH (0.1–1 mM) as
the CII or CI substrate, respectively. The activity was calculated by
measuring the absorbance change at 600 nm and by using the extinc-
tion coefﬁcient of 21.3 mM−1 cm−1 for the dye reduction [30]. The
CII succinate dehydrogenase activity (SDH) was completely inhibited
bymalonate. The activities of both succinate–cytochrome c oxidoreduc-
tase (CII+CIII) and NADH–cytochrome c oxidoreductase (CI+CIII)
were determined using SMPs (25 μg protein/ml) incubated at 37 °C in
50 mM HEPES, pH 7.2, 1 mM cyanide, and 50 μM cytochrome c (from
horse heart). The reaction was started by adding succinate (0.25–
2 mM) or NADH (0.1–1 mM). The activity was assessed in a dual wave-
length spectrophotometer bymeasuring the reduction of oxidized cyto-
chrome c over time from the difference in absorbance at 550 minus
540 nm and by using the extinction coefﬁcient of 19.1 mM−1 cm−1
[31]. The CII oxidoreductase activity was fully blocked by malonate
(2.5 mM) or antimycin (5–10 μM), whereas the CI oxidoreductase
activity was 88% inhibited by 20 μM rotenone.
2.4. ATP determination
The cellular ATP content was determined in cells incubated as de-
scribed above for respiration. The cell samples were treated with 3%
(v/v) perchloric acid and centrifuged; the supernatant was neutral-
ized with 3 M KOH/0.1 M Tris and used for determination of ATP by
the standard enzymatic method with hexokinase and glucose-6-
phosphate dehydrogenase [32].
For this work three different batches of MitoVES were used.
MitoVES, α-TOS and α-TEA were dissolved in 70% ETOH/30% DMSO.
No effect of drug vehicle was observed for any of the measured
parameters.
3. Results
3.1. Mitochondrial respiratory rates
Addition of low (b1 μM) MitoVES concentrations to rat liver
(RLM) or AS-30D hepatoma mitochondria, incubated at 37 °C and
pH 7.2 or 6.8 with either Pyr/Mal, 2-OG or succinate (+rotenone)
(Fig. 1) did not alter the rates of the pseudo-state 4 (before addition
of ADP), state 3 (ADP-stimulated) and state 4 respiration (respiratory
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at concentrations lower than 100 μM did not perturb mitochondrial
respiratory rates (data not shown). At 0.3 mM α-TOS and at pH 7.2
with succinate as substrate, respiratory rates of the pseudo-state 4
and net state 3 (state 3 respiration minus pseudo-state 4 respiration)
were inhibited in AS-30D mitochondria by 40% and 10%, respectively.
Similar inhibition occurred with either 2-OG or Pyr/Mal as substrate.
In marked contrast, α-TOS in the 0.1–0.3 mM range stimulated
pseudo-state 4 respiration by 50–100% and inhibited net state 3
respiration by 20–30% in RLM with succinate or Pyr/Mal at pH 7.2.
Results with higher α-TOS concentrations are less reliable because
the drug becomes less soluble. At 100 μM, α-TEA inhibited pseudo-
state 4 and net state 3 mitochondrial rates in RLM with succinate as
substrate, pH 7.2, by 30%. Similar results were observed in mitochon-
dria from hepatoma cells.
On the other hand, MitoVES stimulated pseudo-state 4 and state 4
respiratory rates in the 1–20 μM range in both hepatoma mitochon-
dria and RLM with either oxidizable substrates (Figs. 1, 2A and B).
The values of half-maximal stimulatory concentration (SC50) required
to accelerate pseudo-state 4 respiration are shown in Table 1.
MitoVES levels of 10–20 μM sufﬁced to reach the maximal stimula-
tion of pseudo-state 4 respiration. With succinate (+rotenone) the
SC50 value for MitoVES in tumor mitochondria was signiﬁcantly
lower than that required for RLM at pH 7.2, whereas statistically sig-
niﬁcant differences were not reached at pH 6.8 (Table 1). In both
types of mitochondria, α-TEA required higher concentration than
MitoVES to stimulate the pseudo-state 4 respiration.
The MitoVES-induced respiratory stimulation was accompanied by
decreased ADP/O ratios and decreased respiratory control values
(Fig. 1). Therefore, MitoVES acting as an uncoupler (H+ ionophore)
inhibited mitochondrial ATP synthesis (i.e., rate of state 3 respiration×
ADP/O ratio, a measure of oxidative phosphorylation, OxPhos) (see
Fig. 1). Then, due to the difﬁculty to calculate ADP/O ratios in the pres-
ence of high MitoVES, the rate of net state 3 respiration was deter-
mined as a more suitable alternative to assess the MitoVES inhibitory
effect on OxPhos and respiratory control ratios (Fig. 2C). Thus, at pHFig. 1. Effect of MitoVES on respiratory rates of tumor and normal mitochondria. Mitochon
incubated in KME buffer at 37 °C with 10 mM succinate+1 μM rotenone, 2 mM Pi and the in
indicate the rates of O2 uptake in nanogram atoms oxygen min−1 mg protein−1 (ngAtO).7.2 or 6.8, succinate-driven OxPhos was more susceptible to MitoVES
in both AS-30D and RLM than that driven by Pyr/Mal or 2-OG
(Table 2). α-TOS andα-TEA also affected the rate of net state 3 respira-
tion in both types of mitochondria, although at signiﬁcantly higher
concentrations (Table 2).
TTFA is a well-known complex II inhibitor that acts in the ubiqui-
none binding site [33,34], which is the proposed site for MitoVES
action [13]. Therefore, as a control of the MitoVES effect on respirato-
ry complex II, the effect of TTFA on mitochondrial energy-dependent
functions was also examined. The succinate-dependent state 3 respi-
ration was potently inhibited by TTFA with IC50 values of 0.45±
0.19 μM (4) and 0.65 μM (2) in AS-30D and rat liver mitochondria,
respectively, and full blockade reached at 10 μM (Fig. S1); state 3
respiration with glutamate plus malate was 50% inhibited by TTFA
at 2.1±0.5 (3) μM and >25 μM (2) in AS-30D and rat liver mitochon-
dria, respectively. Thus, in contrast to MitoVES, TTFA did not stimu-
late O2 uptake but it rather behaved as a respiratory inhibitor at
least in the 10–100 μM range (Fig. S1). Similarly to MitoVES, TTFA
showed preference for tumor over non-tumor mitochondria.
3.2. Mitochondrial membrane potential (Δψm)
Agents like CCCP that induce classical mitochondrial uncoupling
are detected by their ability to stimulate pseudo state 4 and state 4
respiratory rates and inhibit ATP synthesis after collapsing the Δψm.
To ﬁrmly establish the uncoupling behavior of MitoVES in the
1–10 μM range, membrane potential was estimated for both AS-30D
and liver mitochondria in the presence of MitoVES.
With the AS-30D mitochondria incubated at pH 6.8 and in the
presence of succinate+rotenone, 6.7 μM MitoVES induced collapse
of the Δψm, which slowly recovered to a level slightly lower than
the control (in the absence of MitoVES; Fig. 3A). Moreover, the stim-
ulation of ATP synthesis by adding ADP was also clearly affected. In
contrast, at pH 6.8, 6.7 μM MitoVES exerted a negligible effect on
the Δψm generated by RLM (Fig. 3C). At pH 7.2 with 8.1 μM MitoVES
(Figs. 3B and D), Δψm in hepatoma mitochondria did not recover todria (1 mg protein/ml), isolated from AS-30D hepatoma cells (A) or rat liver (B), were
dicated MitoVES (MV11) concentrations. ADP was 200 nmol. The numbers on the traces
Table 1
Half-maximal stimulatory drug concentrations (μM) of pseudostate 4 respiration in
isolated mitochondria.
Substrate Drug RLM Hepatoma RLM Hepatoma
pH 7.2 pH 6.8
Succ+rote MitoVES 5.1±2.7 (6)a,b,c 1.1±1.1 (3)a 12.9±7.6 (4) 2.4±3.7 (3)
α-TEA >100 (3)b 198 >200 (2) >150 (1)
α-TOS >300 (3)c >300 (4) ND >300 (1)
2OG MitoVES 1.7 (2) 0.9 (2) 9.3 (2) 7.6 (1)
α-TOS >300 (1) >300 (3) ND ND
Pyr/Mal MitoVES 13.5 (1) 3.3±2.6 (3) 9.1 (2) 8.5 (2)
α-TEA 50 (1) >200 (1) >200 (1) >100 (1)
α-TOS >300 (1) >300 (1) >300 (4) >300 (2)
In the absence of drugs, the rates of state 4 respiration (steady-state respiratory rate
reached before adding ADP; see Fig. 1) in RLM and hepatoma mitochondria, respectively,
with 1–10 mM succinate (Succ)+1 μM rotenone (rote) at pH 7.2 were 114±43 (n=9)
and 78±47 (n=5); and at pH 6.8, were 121±30 (n=5) and 56.5±18 (n=3); with
10 mM 2OG (+1mM malate for RLM) at pH 7.2, 45 (n=2) and 37.5 (n=2); and at pH
6.8 42 (n=2) and 36 (n=1); with 1 mM Pyr+1 mM (or 0.1–0.3 mM for AS-30D hepa-
toma) Mal at pH 7.2, 42 (n=2) and 64±27 (n=4); and at pH 6.8 37±6 (n=3) and
62 (n=2) ngAO/min/mg protein. aPb0.05; b,cPb0.005; Student t test for non-paired sam-
ples. ND, not determined.
Table 2
Half-maximal inhibitory drug concentrations (μM) of net state 3 respiration in isolated
mitochondria.
Substrate Drug RLM Hepatoma RLM Hepatoma
pH 7.2 pH 6.8
Succ+rote MitoVES 15.7±4.7 (6)a 1.6±1.6 (4)a,b,c 13±8 (4) 10.5±5 (3)d
α-TEA 155 (2) 104 (2) ND 119±52 (3)d
α-TOS >300 (4)c ND >300 (1)
2OG MitoVES 12 (2) 9.5 (2) 8.8 (2) ND
α-TOS >300 (3) >200 (4) ND
Pyr/Mal MitoVES 8.9 (1) 14.7±5 (3)b 15 (2) 12.5 (2)
α-TEA 113 (1) >200 (1) >125 (2)
α-TOS >300 (2) >200 (3) >300 (1)
In the absence of drugs, the rates of net state 3 respiration (state 3 respiration minus
pseudo-state 4 respiration) in RLM and hepatoma mitochondria, respectively, with
1–10 mM succinate (Succ)+1 μM rotenone (rote) at pH 7.2 were 340±112 (n=9)
and 78±28.5 (n=5); and at pH 6.8, were 338±23 (n=5) and 89±17 (n=3);
with 10 mM 2OG (+1 mM malate for RLM) at pH 7.2, 171.5 (n=2) and 33 (n=2);
and at pH 6.8 261 (n=2) and 112 (n=2); with 1–2 mM Pyr+1 mM (or 0.1–0.3 mM
for AS-30D hepatoma) Mal at pH 7.2, 96 (n=2) and 164±82 (n=4); and at pH 6.8,
94±43 (n=3) and 228 (n=2) ngAO/min/mg protein. a,b,cPb0.005; dPb0.025; Stu-
dent t test for non-paired samples. ND, not determined.
0 5 10 18 20
0
1
2
6
A
B
C
Succ + Rot
Pyr + Mal
St
im
ul
at
io
n 
of
 S
ta
te
 4
 R
es
pi
ra
tio
n 
(F
old
)
0
1
2
3
4
5
6
Pyr + Mal
Succ + Rot
St
im
ul
at
io
n 
od
 S
ta
te
 4
 R
es
pi
ra
tio
n 
(F
old
)
0.0
0.2
0.4
0.6
0.8
1.0
RLM + Pyr/Mal
AS-30D + Pyr/Mal
RLM + SuccAS-30D + SuccN
et
 S
ta
te
 3
 R
es
pi
ra
tio
n
[MV11], μM
0 5 10 18 20
[MV11], μM
0 5 10 18 20
[MV11], μM
Fig. 2. Effect of MitoVES on mitochondrial respiratory rates. Stimulation of state 4 res-
piration in hepatoma (A) and rat liver (B) mitochondria. (C) Net state 3 respiration in
AS-30D hepatoma and rat liver (RLM) isolated mitochondria with the indicated sub-
strates. The results shown are representative of two–three experiments with similar
outcomes, except for those shown with dispersion bars. For clarity, the dispersion
bars represent the standard error of the mean.
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fully collapsed in hepatoma mitochondria (not shown), whereas liver
mitochondria were still able to generate a small Δψm signal (Fig. 3C
and D). In contrast to the observations with succinate, in both types
of mitochondria with Pyr/Mal as substrate 10 μM MitoVES did notinduce collapse of the Δψm, although higher concentrations (≥15 μM)
did fully collapse the H+ gradient (data not shown).
The effect of MitoVES on Δψm may be attributed to the inhibition
of electron transport rather than to uncoupling. Depending on the
concentration, respiratory inhibitors can induce changes in Δψm sim-
ilar to those shown in Fig. 3. Therefore, Δψm driven by ATP hydrolysis
in isolated mitochondria incubated with increasing MitoVES concen-
trations was determined to evaluate its possible uncoupling effect
on a system not depending on the respiratory chain activity. With
4.7 μMMitoVES and at pH 6.8, the generation of Δψm in AS-30D hep-
atoma mitochondria was severely affected (Fig. 4A), whereas this
required 6.75 μM MitoVES before the membrane potential in RLM
was similarly depressed (Fig. 4B). TTFA at 10 μM induced a negligible
or slight decrease (b15%) in the Δψm driven by ATP hydrolysis in RLM
and AS-30D mitochondria at pH 7.2 (Fig. S2). At 19 μM, TTFA slowly
collapsed the ATP-driven Δψm in both types of mitochondria. At
38 μM, TTFA completely collapsed Δψm in hepatoma mitochondria,
whereas this energy parameter was slowly affected in RLM. For full
and rapid collapse of the Δψm in RLM, addition of 100 μM TTFA was
required (Fig. S2). The collapse of the Δψm driven by ATP hydrolysis
induced by 10 μM MitoVES was not prevented by 10 μM TTFA (data
not shown).
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membrane potential. The results shown are representative of two independent exper-
iments with similar outcomes.
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The rate of ATP hydrolysis in well-coupled liver (60–106 nmol hy-
drolyzed ATP/min/mg protein at 37 °C) and AS-30D mitochondria
(45 nmol hydrolyzed ATP/min/mg protein at 37 °C) was markedly
(25–270%) stimulated by 2–10 μMMitoVES; in turn, CCCP was unable
to further stimulated the rate of ATP hydrolysis induced by 10 μM
MitoVES. At 15–20 μMMitoVES, the ATP hydrolysis was also stimulat-
ed although at a lower extent than that attained at 10 μM. TTFA at
25 μM induced 86% stimulation of ATP hydrolysis in AS-30D mito-
chondria. These results indicated that MitoVES at 1–10 μM stimulates
ATP hydrolysis acting as an uncoupler and does not inhibit the activ-
ities of the mitochondrial ATP synthase (catalyzing the reverse reac-
tion as an ATPase) and adenine nucleotide translocase, both
required for ATP hydrolysis in intact mitochondria.
3.4. Ca2+ release
AS-30D hepatoma mitochondria showed higher capacity for Ca2+
uptake than RLM as it has also been reported for Ehrlich ascites mito-
chondria [35]. The Ca2+ uptake by RLM was fully abolished by 20 μM
MitoVES (data not shown). In turn, Ca2+ release was immediately in-
duced by 2 μMMitoVES or CCCP, or was induced after a short delay atlower doses in both AS-30D and liver mitochondria (Fig. 5). α-TEA in
the 30–90 μM range did not promote Ca2+ release (data not shown).
3.5. Uncoupled respiration
To examine for the possible inhibitory effect of MitoVES on mito-
chondrial respiratory enzymes, the rate of uncoupled respiration
was determined. In the presence of an excess of an uncoupler, only
the inhibitory effect of MitoVES would become apparent, as long as
the site of action is localized to the respiratory chain complexes. How-
ever, in case of MitoVES targeting the Krebs cycle enzymes, ATP
synthase, adenine nucleotide translocase or the Pi carrier, no effect
of this agent on uncoupled respiration is anticipated.
The rate of uncoupled respiration (0.5–1 μM CCCP) in AS-30D
hepatoma or liver mitochondria was not affected by b10 μMMitoVES
or b100 μM α-TOS in 2 or 15 min pre-incubations with succinate
(+rotenone) or 2-OG as the oxidizable substrate, and at either pH
7.2 or 6.8 (data not shown). At 100 μM MitoVES, 71–97% inhibition
of uncoupled respiration was achieved with succinate or 2-OG
as the substrate in both AS-30D or liver mitochondria at pH 7.2.
With α-TEA, half-maximal inhibitory concentration (IC50) values of
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Fig. 5. Effect of MitoVES on Ca2+ release in hepatoma (A) and (B) rat liver mitochondria. Traces from different experiments were overlapped. Arrows indicate addition of MitoVES at
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ration in AS-30D and rat liver mitochondria, respectively, incubated
with succinate at pH 7.2.
3.6. Respiratory rates in sub-mitochondrial particles
It could be argued that in uncoupled mitochondria MitoVES as a
lipophilic cation may not be efﬁciently accumulated, because no elec-
trical gradient (negative inside) would exist under such conditions,
which is required to facilitate localization of the drug at the interface
of the inner mitochondrial membrane and the matrix. Therefore,
SMPs were prepared to allow for the direct exposure of the respirato-
ry chain complexes to the three different VE analogues. SMPs are in-
side–out vesicles, in which the matrix side of the inner membrane is
exposed to the incubation medium. To assess the orientation and in-
tegrity of these vesicles, they were examined for their ability to oxi-
dize NADH (which is not oxidized in intact mitochondria) and to
build a pH gradient (which is determined using a permeable amine;
in mitochondria, the acidic pH is on the outer side and hence the
amine does not permeate). A pH gradient (>1.5) was established in
SMPs and the oxidation of NADH was substantial (421–1040 ng atom
oxygen min−1 mg protein−1 at 37 °C and pH 7.4 with 1 mM NADH;
with 0.3 mM NADH plus 1 mM MgCl2, activity was 1265±100 ng
atom oxygen min−1 mg protein−1; n=5), all of which indicated that
the SMP preparations consisted of inside–out vesicles.
The IC50 values of the respiration rate with succinate as the sub-
strate for MitoVES, α-TEA and α-TOS were 47±7 (n=3), 37
(n=2) and 170 μM (n=2), respectively, whereas for NADH as the
substrate they were 30, 30 and 194±18 μM (n=3), respectively. Ad-
dition of Mg2+ slightly stimulated the respiratory rates in SMPs
(Fig. 6), diminishing the drug potency with succinate or NADH as
the oxidizable substrate (>100 μM for MitoVES and α-TEA; and
>200 μM for α-TOS), except for MitoVES and NADH (IC50=28 μM)
(Fig. 6). In the experiments where SMPs were pre-incubated with
MitoVES or α-TEA for longer periods and with succinate as thesubstrate, the uncoupling effect of these two drugs became apparent
at their lower concentrations (assessed on the basis of stimulation of
respiration), while the inhibitory effects on respiration were exerted
by these agents at higher concentrations.
3.7. Oxidoreductase and dehydrogenase activities of complexes I and II
In order to further assess the relative efﬁcacies and speciﬁcities of
MitoVES, α-TEA and α-TOS, the effects of these drugs on the
dehydrogenase and oxidoreductase activities of CI and CII were ex-
amined using SMPs. MitoVES disrupted the oxidoreductase activity
of CII (i.e., electron transfer from CII to CIII) at relatively low doses
(IC50 of 5–7 μM; Table 3). The addition of Tween 20 diminished the
efﬁcacy of the agent (IC50 of 23; n=2; and 39±16 μM; n=4, for
low and high succinate, respectively). In contrast, MitoVES exerted
no discernible effect on the oxidoreductase activity of CI (Table 3).
Longer-term experiments (15 min) with or without Mg2+ did not
improve the drug efﬁcacy (data not shown). Similarly, TTFA inhibited
CII oxidoreductase activity with an IC50 of 12 μM (in the absence of
Tween 20), reaching 80% blockade at 75–100 μM (data not shown);
CI oxidoreductase activity was not affected by 100 μM TTFA.
α-TEA and α-TOS affected the CII dehydrogenase activity at
similar or slightly higher concentrations than those required for its
inhibition by MitoVES, whereas the CII oxidoreductase activity was
signiﬁcantly less sensitive. The CII dehydrogenase activity was less
sensitive than the oxidoreductase activity to MitoVES, as previously
reported [13]. The CI dehydrogenase and oxidoreductase activities
were not affected by the three drugs at concentrations below
100 μM (Table 3).
3.8. Cellular respiratory rates, Δψm and ATP content
The rate of respiration of the intact hepatoma cells was stimulated
byMitoVES in the 1–10 μMrange,whereas the sensitivity to oligomycin
was decreased at higher concentrations (Figs. 7 and 8). This response
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respiration and inhibition of OxPhos, which is equal to the rate of
oligomycin-sensitive respiration). Interestingly, the OxPhos rates of
AS-30D hepatoma cells and human HeLa carcinoma cells were more
sensitive to MitoVES than those of rat hepatocytes (Fig. 8, Table 4),
and the agent was effective at relatively lower doses than those re-
quired for other anti-cancer drugs acting via mitochondria [reviewed
in 1]. However, the uncoupling effect induced by 10 μM MitoVES in
hepatocytes and HeLa (Figs. 7 and 8) cells was not as potent as that
attained with the AS-30D cells. These results (Fig. 8) clearly indicate
that the predominant effect of MitoVES at low doses (1–10 μM) in
human cancer cells is to lower OxPhos rates by acting as an uncoupler.TTFA (100–250 μM) did not affect the total respiration rates in AS-30D
cells but strongly inhibited the oligomycin-sensitive respiration
(OXPhos) (data not shown).
High concentrations (200–300 μM) of α-TEA or α-TOS did not
show any effects on either the total respiration or OxPhos rates in
rat hepatoma or HeLa cells even after incubations for 5–15 min at
37 °C (data not shown).
The Δψm was also directly assessed in intact cells following the
ﬂuorescence signal of rhodamine 6G [25,26]. To ensure that the signal
was reliably monitoring Δψm the effect of oligomycin, a speciﬁc
mitochondrial ATP synthase inhibitor, and the uncoupler CCCP was
determined. After reaching a stable signal, the addition of oligomycin
Table 3
Vitamin E analogue IC50 (μM) values on respiratory chain complexes in beef heart
SMPs.
Compound Activity Succ (mM) NADH (mM)
0.25–0.5 2 0.1 1
MitoVES Dehydrogenase 44±28 (3) 60±20 (3)a >100 (3) >100 (1)
Oxidoreductase 7.4±5.5 (3)b 5.6±5.2 (5)a,c 46.7 (2) >100 (4)c
α-TEA Dehydrogenase 20 (1) 33.6 (1) ND >250 (1)
Oxidoreductase 131±23 (3)b 37.6 (1) >150 (1) >100 (2)
α-TOS Dehydrogenase 39 (2) 32 (1) >100 (2) ND
Oxidoreductase >100(2) >100(3) >100(1) >100 (2)
Dehydrogenase and oxidoreductase activities were determined after 10–15 min
incubation with the drugs at 37 °C. Absolute values of dehydrogenase activities were in
the range of 70–150 for 0.25–0.5 mM succinate; 90–270 for 2 mM succinate; 355–700
for 0.1 mM NADH; and 744–1100 nmol/min/mg protein for 1 mM NADH, respectively.
Absolute values of oxidoreductase activities were 195–400 for 0.25–0.5 mM succinate;
70–350 for 2 mM succinate; 212–418 for 0.1 mM NADH; and 307–1076 nmol/min/mg
protein for 1 mM NADH, respectively. Values represent media±standard deviation; (n);
Succ, succinate, ND, not determined. a,bPb0.005
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crease in Δψm because oligomycin fully and speciﬁcally blocks
OxPhos, the mitochondrial pathway that consumes Δψm to synthesize
ATP. To speciﬁcally and completely collapse the Δψm, CCCP was added
(Fig. 9). The magnitude of the Δψm generated by AS-30D cells was ap-
preciably higher than that achieved by rat hepatocytes (136±46 ar-
bitrary ﬂuorescence units (n=4) vs. 68 arbitrary ﬂuorescence units
(n=2) in AS-30D cells and hepatocytes, respectively). The difference
in Δψm between both types of cells might be attributed to differences
in the number of living cells used as the tumor cells showed cell
viabilities greater than 95% whereas hepatocytes only were 60–80%
viable. However, the magnitude of the Δψm in AS-30D cells doubled
that in hepatocytes. Similar results have been described by others
[36,37; reviewed in 1]. MitoVES at 2 μM induced signiﬁcant collapse of
the Δψm in tumor cells but it was innocuous in hepatocytes (Fig. 9).
This difference in MitoVES sensitivity between tumor and non-tumor
cells was also reproducible at lower cell numbers, but requiring lower
MitoVES concentrations (data not shown). TTFA at 10–25 μM induced
a less profound partial collapse of the Δψm (Fig. 9).Fig. 7. Cellular respiration of (A) AS-30D hepatoma, (B) rat hepatocyte and (C) HeLa carcinom
numbers on the traces indicate the rates of O2 uptake in nanogram atoms oxygen min−1 mTo further assess whether the MitoVES-induced abolishment of
OxPhos in cancer cells also leads to signiﬁcant cellular ATP depletion,
compromising cellular homeostasis, the content of cellular ATP was
determined. In the presence of the drug at concentrations that
severely diminished OxPhos ([MitoVES]>OxPhos IC50), it was found
that MitoVES caused substantial lowering of the ATP levels in AS-
30D and HeLa cells, and in normal hepatocytes (Table 4). However,
in the AS-30D and HeLa cells, the ATP depletion was by 73–81% at
10–11 μM MitoVES, whereas in hepatocytes it decreased by 62–78%
at 37 μM MitoVES (see Table 4) in 15–30 min-incubations. Remark-
ably, at 10 μM MitoVES, the OxPhos rate and ATP content were only
slightly altered (~18%) in hepatocytes after 30 min-incubation at
37 °C (Table 4).
Longer-term incubations (60 min) increased the MitoVES efﬁcacy
to induce maximal ATP depletion neither in the AS-30D tumor cells
(from 10.4 to 2.1 nmol/mg protein; using 11 μM MitoVES) nor in
hepatocytes (from 3.6 to 0.6 nmol/mg protein; with 37 μMMitoVES).
On the other hand, incubation of HeLa cells for 60 min with 3.5 μM
MitoVES caused signiﬁcant ATP depletion of 47%, contrasting with
the negligible drug effect after 15 min incubation (Table 4).
4. Discussion
4.1. Targeting of tumor mitochondria
One of the major problems with current cancer chemothera-
peutic treatments is their lack of speciﬁcity, leading to multiple se-
vere side-effects. Therefore, it is imperative to develop novel anti-
cancer drugs, which can speciﬁcally target malignant cells leaving
normal cells unscathed. The promising drugs α-TOS and its deriva-
tives are efﬁciently hydrolyzed and inactivated by normal cells with
high esterase activity, whereas they are not hydrolyzed in cancer
cells due to low esterase activity. Moreover, these agents interact
with speciﬁc cellular targets, leading to apoptosis and death of can-
cer cells [13,14, reviewed in 16]. Another feature of α-TOS and its
derivatives as anti-cancer drugs is their stronger inherent efﬁcacy
at acidic pH, which commonly exists in the tumor microenviron-
ment. Most cancer cells exhibit enhanced glycolytic activity anda cells. Added cellular proteins and MitoVES (MV11) concentrations are indicated. The
g protein−1 (ngAtO). Oligo, 5 μM oligomycin.
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and, in particular extracellular pH as compared to normal cells
[reviewed in 38].Table 4
MitoVES effect on OxPhos and ATP content in normal and tumor cells.
OxPhos IC50
(μM), 2–15-min
incubation
ATP content
(nmol/mg protein)
Control
Rat
AS-30D Hepatoma 1.4±1 (5) 15-min incubation: 10.4±
30-min incubation: 10.5±
Hepatocytes 61±9 (4) 15-min incubation: 5.2±
30-min incubation: 4.6±
Human
Cervix HeLa 3.5±0.7 (3) 15-min incubation: 4.4±
30-min incubation: 4.6±
60-min incubation: 4.2±
Rat hepatocytes (35 μM), rat hepatoma (11 μM) and human tumor cells (3.5 μM) were inc
OxPhos values were 15±9 (5); 12±6 (4); and 10±6 (6) ngAO/min/mg protein for AS-3
batch, OxPhos IC50 was 11±4 (n=4) in hepatoma cells. Because of the experimental varia
obtained with the ﬁrst MitoVES batch were only included in the table. Values represent me
parentheses.
a Pb0.005 versus control.
b Pb0.01.
c Pb0.025.
d Pb0.05.Previous efforts to increase targeting of anti-cancer drugs have in-
volved the administration of lipophilic cations. This approach is based
on the signiﬁcantly higher electrical potential across both plasma and
inner mitochondrial membranes (Δψp and Δψm, respectively) in can-
cer cells and mitochondria than in their respective normal counter-
parts [36,37; reviewed in 1, 39]. Consequently, lipophilic cations are
accumulated to a larger extent inside cancer cells and their mitochon-
dria, leading to the collapse of Δψp and Δψm, ATP depletion and cellu-
lar death [reviewed in 1]. Hence, the highly lipophilic and delocalized
positive charge of MitoVES explains its signiﬁcantly greater selectivity
towards tumor mitochondria [13].
4.2. Efﬁcient mitochondrial uncoupling and moderate CII inhibition by
MitoVES
In the 1–10 μM range MitoVES exerted a potent uncoupling effect
on both isolated mitochondria and intact hepatoma cells, which
resulted in the stimulation of basal (state 4 and pseudo state 4) respi-
ration and ATP hydrolysis, and inhibition of mitochondrial ATP syn-
thesis (c.f. Figs. 2 and 8A). To unambiguously establish whether
MitoVES behaved as an uncoupler, other energy-dependent parame-
ters were assessed in isolated mitochondria. Membrane potential
and Ca2+ release were more sensitive mitochondrial parameters
than respiration and ATP hydrolysis for detecting the MitoVES
uncoupling effect, regarding response times and the doses required.
At the same 1–10 μM range, MitoVES diminished Δψm and induced
Ca2+ release of tumor and normal mitochondria (c.f. Figs. 3–5), as
do classical uncouplers [40,41].
The inhibition of net state 3 respiration in mitochondria by low
MitoVES (c.f. Fig. 2C; Table 3) correlated with lowering of the tumor
cell OxPhos (c.f. Fig. 8). Indeed, OxPhos of both human HeLa
carcinoma and rodent AS-30D hepatoma cells was affected (Fig. 8)
at relatively lowMitoVES levels (1–3 μM; Table 3), while the MitoVES
IC50 for net state 3 respiration in hepatoma mitochondria was 1.6 μM
(Table 2). However, at 1–3 μM MitoVES, the ATP levels were only
slightly affected (Table 4), indicating the onset of compensatory
mechanisms that preserve the cellular ATP homeostasis, possibly
glycolysis activation and decreased ATP demand. On the other hand,
at 10–11 μMMitoVES sufﬁced to induce severe cellular ATP depletion
in tumor cells, compromising cellular integrity (c.f. Table 4).
Conceivably, several lipophilic drugs with delocalized net posi-
tive charge (clotrimazole, rhodamine 123, MKT-077) and the
DNA-intercalators benzophenone guttiferone-A [42] and doxorubi-
cin [43], may also signiﬁcantly impair the mitochondrial function+[MitoVES]
3.3 (5) 8.5 (2)+[3.5 μM] 1.9±0.4 (3)a+[11 μM]
3.9 (5) 9.7 (2)+[3.5 μM] 2±0.6 (3)b+[11 μM]
0.8 (6) 3.6±0.5 (4)b+[10 μM] 2±0.6 (3)a+[37 μM]
0.5 (4) 3.8±0.2 (4)c+[10 μM] 1±0.5 (3)a+[37 μM]
2.2 (6) 4±3 (3)+[3.5 μM] 2.1±1.1 (3)d+[10 μM]
2.1 (7) 4.1±3.1 (4)+[3.5 μM] 2.3±1 (3)+[10 μM]
1.2 (6) 2.3±1 (3)d+[3.5 μM] 1.7±0.7 (3)c+[10 μM]
ubated with variable concentrations of MitoVES for the indicated times at 37 °C. Total
0D hepatoma, HeLa and rat hepatocytes, respectively. For a different second MitoVES
bility observed when taking all values into account (IC50=6.3±6, n=9), the results
dia±standard deviation, with the number of different preparations assayed between
Fig. 9.Mitochondrial electrical membrane potential in AS-30D hepatoma cells (A) and rat hepatocytes (B). The change in the ﬂuorescence signal of rhodamine 6G was determined
as described under Material and methods. Open block arrow indicates the addition of either MV11 or TTFA (TTF). Abbreviations: CCP, 5 μM CCCP; MV11, MitoVES; Oligo, 5 μM
oligomycin; RH, rat hepatocytes. The experiments shown are representative of 4 and 2 independent AS-30D cell and hepatocytes preparations, respectively, with similar reproduc-
ible results.
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synthase and ANT inhibition; mtDNA decrease) in tumor mitochon-
dria. However, the doses required for the activity of these anti-
neoplastic drugs are 7–10 times higher than those required for
MitoVES to affect the mitochondrial bioenergetics of cancer cells
[reviewed in 1,44,45]. Therefore, MitoVES is an attractive drug for
the use in clinical trials given its activity at relatively low concentra-
tions and its apparently negligible side-effects [13]. Furthermore,
low MitoVES concentrations that drastically decrease OxPhos also
cause substantial growth suppression in aggressive, fast-growing
carcinomas with IC50 values of 3.9 μM, 20 μM and 15 μM after 24 h
for HeLa, breast MCF-7 and prostate PC3 cells, respectively. This in-
dicates that mitochondria-targeted drugs epitomized by MitoVES
show a considerable potential to control metastatic and aggressive
behavior of cancer cells.
Recent reports [12,13,44] have documented that the preferred tar-
get for the action of MitoVES in cancer cells is the respiratory CII. To
further extend this observation, the effects of α-TOS and α-TEA on
the dehydrogenase and oxidoreductase activities of CII in SMPs
were compared to those of MitoVES. As the control, the dehydroge-
nase and oxidoreductase activities of CI were also examined.
The CII oxidoreductase activity was signiﬁcantly more sensitive to
MitoVES than the dehydrogenase activity (c.f. Table 3). The effect of
MitoVES on CII involves interactions of the succinyl-tocopheryl moie-
ty of the agent with the ubiquinone binding site of CII [13], as shown
earlier also for the less efﬁcient α-TOS [14]. Therefore, MitoVES may
differentially affect the two CII activities. Indeed, kinetic analysis of
the type of inhibition of the CII oxidoreductase activity by MitoVES
yielded a complex pattern characterized by mixed inhibition at
concentrationsb50 μM and uncompetitive inhibition at 50–200 μM
(data not shown). The CI dehydrogenase and oxidoreductase
activities were unaffected by 100 μM or lower MitoVES concentra-
tions (c.f. Table 3). These results clearly established that MitoVES
preferentially associates with CII and not with CI or CIII [12,13]. More-
over, it has been recently documented that the interaction of MitoVES
speciﬁcally with CII induces ROS production and apoptosis within rel-
atively short times in several different cancer cell lines [13,44].
The TPP+-lacking α-TOS and α-TEA were also effective in
inhibiting CII activities, albeit to a lesser extent. However, it should
be noted that in SMPs, the succinate binding site is freely accessible
(i.e., the drugs do not need to traverse the hydrophobic core of the
inner mitochondrial membrane to interact with CII) and therefore
the reason why these drugs were less potent than MitoVES in intact
mitochondria is probably due to their lower permeability across the
inner membrane. This issue still needs to be resolved.MitoVES was found more efﬁcient than α-TOS or α-TEA at induc-
ing mitochondrial dysfunction in intact cells. In fact, α-TOS and
α-TEA at 100–300 μM did not affect the respiratory rates and OxPhos
in hepatocytes and hepatoma cells (c.f. Tables 1, 2 and 4). This obser-
vation correlates with the relatively low efﬁcacy of α-TOS to induce
apoptosis in Jurkat cells compared to MitoVES (MitoVES is 1–2 orders
of magnitude more apoptogenic than α-TOS) [13,44]. A possible ex-
planation for these differences may be that cancer mitochondria
in situ maintain greater Δψm than normal mitochondria [reviewed
in 1], and this drives the lipophilic cationic MitoVES to penetrate
and accumulate at the inter-phase of the mitochondrial matrix and
the inner membrane [13,44], whereas α-TOS and α-TEA with no net
positive charge associate indiscriminately with cellular hydrophobic
structures. Preferential distribution at the mitochondrial matrix–inner
membrane inter-phase has also been reported for mitochondrially
targeted redox-active compounds, the prime example being the
mitochondrially targeted coenzyme Q (MitoQ) [45,46].
Isolated tumor mitochondria and tumor cells were 2–7 and 3–10
times, respectively, more sensitive to the MitoVES effects (when
uncoupling and inhibiting OxPhos) than normal mitochondria and
cells (c.f. Figs. 2 and 8 and Tables 1, 2 and 4), indicating exceptionally
high cancer cell selectivity of MitoVES. This highly intriguing feature
of MitoVES has also been documented when analyzing its effects on
the growth of several different cancer cell lines and on the kinetics
of progression of tumors in mouse models [12,13,44]. The molecular
mechanism of the selectivity of the drug for malignant cells also in-
volves the inherently higher esterase activity in normal cells versus
the low or negligible activity found in cancer cells [47], since the
esterase in normal cells releases the succinyl moiety of the VE ester
analogues, thwarting their anchoring ability to combine with and in-
hibit CII.
In conclusion, the results presented in this work support the fol-
lowing sequence of events for MitoVES action on cancer cells and
their mitochondria. At low doses (1–10 μM), increased uptake of
MitoVES promotes Δψm dissipation which in turn inhibits OxPhos
and stimulates O2 consumption, leading to ATP depletion. At moder-
ate doses of 10–20 μM, MitoVES inhibits the oxidoreductase activity
of CII, while at 40–60 μM, the dehydrogenase CII activity is inhibited;
CI and CIII activities are inhibited at substantially higher MitoVES
concentrations. Inhibition of CII activity by MitoVES brings about
the additional deleterious effect of increasing ROS production. Collec-
tively, our ﬁndings strongly point to the mitochondrially targeted VE
analogue MitoVES as a suitable and highly promising candidate for
cancer therapy, acting in a multi-task manner and being highly selec-
tive for cancer cell mitochondria [1–14,44].
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